RIYADH – October 28, 2025: Global health technology company M42 has announced the launch of M42 Saudi Arabia, marking a significant expansion of its regional operations and deepening its strategic partnership with the Kingdom. The announcement was made during the Global Health Exhibition in Riyadh, underscoring the company’s commitment to advancing Saudi Arabia’s Vision 2030 healthcare transformation.
Building on over 12 years of collaboration with the Saudi Ministry of Health—where M42 operates 40 Diaverum clinics across 33 cities—the new entity will extend its scope beyond renal care to include omics, population health, digital health integration, and the management of metabolic and lifestyle diseases.
The creation of M42 Saudi Arabia is designed to accelerate Saudi-led research and development, foster clinical trials, and scale digital health and precision medicine initiatives, supporting the Kingdom’s transition toward a preventive and predictive healthcare model.
“M42 Saudi Arabia is a natural step in building a globally scaled health intelligence ecosystem in partnership with local institutions,” said Dimitris Moulavasilis, Group CEO of M42. “Our mission is to combine technology, data, and clinical excellence to enhance healthcare outcomes across the region.”
Ziyad Kabli, COO for the Middle East and Asia, added, “Our focus is expanding from specialty services to system-wide collaboration in advanced healthcare, enabling the Kingdom to become a hub for medical innovation and digital transformation.”
This milestone follows M42’s growing regional footprint, which includes:
- Launching Jordan’s first virtual hospital, the Digital Health Centre.
- Partnering with Mumtalakat in Bahrain to deliver long-term and post-acute care through Amana Healthcare – Bahrain.
The establishment of M42 Saudi Arabia positions the company as a key enabler of the Kingdom’s AI- and genomics-driven health ecosystem, supporting its long-term vision of accessible, personalized, and sustainable healthcare.
